跳转至内容
Merck

SML2020

Sigma-Aldrich

阿曲生坦 盐酸盐

≥98% (HPLC)

别名:

2R-(4-甲氧基苯基)-4S-(1,3-苯并二恶唑-5-基)-1-(N,N-二(正丁基)氨基羰基甲基)-吡咯烷-3R-羧酸盐酸盐, ABT-627盐酸盐, 盐酸A-147627, (2R,3R,4S)-4-(1,3-苯并二恶唑-5-基)-1- [2-(二丁基氨基)-2-氧乙基] -2-(4-甲氧基苯基)-3-吡咯烷羧酸盐酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C29H38N2O6 · HCl
分子量:
547.08
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

[H]Cl.CCCCN(CCCC)C(CN1C[C@H](C2=CC=C(OCO3)C3=C2)[C@@H](C(O)=O)[C@@H]1C4=CC=C(OC)C=C4)=O

InChI

1S/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34);1H/t23-,27-,28+;/m1./s1

InChI 密鑰

IJFUJIFSUKPWCZ-SQMFDTLJSA-N

一般說明

阿曲生坦也已用于治疗心血管疾病。

生化/生理作用

阿曲生坦是一种选择性内皮素 ETA 受体拮抗剂,ETA 的 IC50 为 0.2 nM,而 ETB 受体的 IC50 为 190 nM。它阻断内皮素诱导的细胞增殖,已被研究作为前列腺癌的一种潜在疗法,最近又被用于糖尿病肾病的疗法。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Carmen De Miguel et al.
Scientific reports, 7, 43152-43152 (2017-02-24)
Endothelin-1 (ET-1) promotes renal damage during cardiovascular disease; yet, the molecular mechanisms involved remain unknown. Endoplasmic reticulum (ER) stress, triggered by unfolded protein accumulation in the ER, contributes to apoptosis and organ injury. These studies aimed to determine whether the
Margien G S Boels et al.
Diabetes, 65(8), 2429-2439 (2016-05-22)
Atrasentan, a selective endothelin A receptor antagonist, has been shown to reduce albuminuria in type 2 diabetes. We previously showed that the structural integrity of a glomerular endothelial glycocalyx is required to prevent albuminuria. Therefore we tested the potential of
Determination of atrasentan by high performance liquid chromatography with fluorescence detection in human plasma.
Bryan P D, et al.
Biomedical Chromatography, 15(8), 525-533 (2001)
Chunhua Jin et al.
The Journal of pharmacology and experimental therapeutics, 351(2), 467-473 (2014-09-06)
Experiments determined whether the combination of endothelin A (ETA) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门